Direxion Healthcare Bull 3X

M Holdings Increases Stake in AbbVie, Analysts Upgrade Rating

M Holdings Increases Merck Holdings to 47,025 Shares

Mirabella Financial Services LLP reduced its stake in AbbVie

Forbes Analyzes UnitedHealth Group's 2026 Stock Outlook, Focusing on Medical Care Ratio

Lilly Asia Ventures Co-leads $53 Million Financing for SciNeuro Pharmaceuticals, Focusing on CNS Diseases

AbbVie Sponsors Workshop Discussing Treatment of Platinum-Resistant Ovarian Cancer at ESMO Asia

Multiple institutional investors disclose increased stakes in UnitedHealth Group.

UnitedHealth Group will go ex-dividend on December 8, 2025, with a dividend of $2.21 per share

UnitedHealth Group stock falls on heavy volume, hitting intraday lows

OTR Therapeutics, co-funded by Lilly Asia Ventures, announced the completion of a $100 million Series A financing

Republican healthcare plan will include PBM reform, according to a report

Eli Lilly provides an additional $25 million in funding to Adverum Biotechnologies as per acquisition agreement.

Merck Raises $8 Billion Through Multiple Tranches of Notes

UnitedHealth Stock Declines 1.83% Amid Legal and Regulatory Pressures

FDA Approves Merck's New Parasitic Drug for Cattle

Sina Finance In-depth Report: How Weight-Loss Drugs Propelled Eli Lilly to a Trillion-Dollar Pharmaceutical Giant

UnitedHealth Group options trading volume surges, with call options dominating

FDA Senior Official Richard Pazdur's Retirement Sparks Industry Attention

US Insurers Face Multiple Challenges Including Cost Increases

ISPE Announces Keynote Speakers and Technical Themes for the 2026 Future Facilities Conference

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

Dividend Roundup: Microsoft, UnitedHealth Group, Analog Devices, Nucor, and more

businessinsider

NU Holdings

Nucor

Unitedhealth

Analog Devices

Microsoft

Dividend Roundup: Microsoft, UnitedHealth Group, Analog Devices, Nucor, and more

ABBV

M Holdings Securities Inc. increased its holdings in AbbVie Inc. by 68.6% in Q2, owning 16,979 shares worth $3,121,000. Several other institutional investors also adjusted their positions in AbbVie. Analysts have upgraded AbbVie's stock ratings, with a current average rating of "Moderate Buy" and a target price of $241.85. AbbVie reported Q3 earnings of $1.86 EPS, beating estimates, and increased its quarterly dividend to $1.73 per share. The company has a market cap of $404.17 billion.

Market Beat

Abbvie

M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV

M Holdings Securities Inc. increased its stake in Merck & Co., Inc. by 55.7% in Q2, owning 47,025 shares valued at $3.72 million. Other investors also adjusted their holdings. Merck's stock opened at $100.85, with a market cap of $250.31 billion. The company reported Q3 earnings of $2.58 per share, surpassing estimates, and increased its quarterly dividend to $0.85 per share.

Merck

M Holdings Securities Inc. Boosts Stake in Merck & Co., Inc. $MRK

The article analyzes UnitedHealth's stock outlook for 2026, focusing on the Medical Care Ratio (MCR) impact on profitability. It presents three scenarios: stabilization, recovery, and further deterioration, each affecting EPS and share price. Key assumptions include premium revenue, baseline MCR, EPS, and Optum earnings. The article also suggests the High Quality Portfolio for less volatile returns.

Forbes

UNH Stock In 2026: Bull And Bear Case Scenarios

Mirabella Financial Services LLP reduced its stake in AbbVie Inc. by 69.5% in Q2, owning 12,919 shares worth $2.41 million. Other institutional investors adjusted their positions in AbbVie. Analysts have varied ratings, with a consensus of "Moderate Buy" and a target price of $241.85. AbbVie reported Q3 earnings of $1.86 EPS, beating estimates, and increased its dividend to $1.73 per share. The stock opened at $228.68, with a market cap of $404.17 billion.

Mirabella Financial Services LLP Has $2.41 Million Position in AbbVie Inc. $ABBV

House Republicans, led by Speaker Mike Johnson, plan to introduce a GOP-only health care bill next week. The bill aims to address ACA subsidies, but specifics are not yet disclosed. It is expected to be presented before the year's end, with significant developments anticipated early next week.

Unusual Whales

Johnson & Johnson

GOP to unveil GOP-only health care bill next week per Speaker Mike Johnson, expected to address ACA subsidies, with 'big developments' to come early next week.

An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.

PR Newswire

 AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

NVDA

AAPL

Following significant recent losses, the stock market is in need of a strong rebound. Investors are advised to keep a close eye on Nvidia, Apple, and Eli Lilly. Dow Jones Futures have seen a promising rise, while Novo Nordisk has experienced a significant dip. This update emphasizes the importance of monitoring these key companies for potential shifts in the market.

NVIDIA

Eli Lilly

Apple

Dow Jones futures up, Novo Nordisk down. Market recovery needed after recent losses. Nvidia, Apple, Eli Lilly in focus.

HALO

Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

marketscreener

Halozyme Therap

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

ULTA

Small-cap stocks are nearing all-time highs as Dow Jones futures surge. Eli Lilly's stock is at a critical level, while Ulta Beauty reports strong earnings. Robinhood leads new stock purchases, and five stocks are in buy zones, indicating promising investment opportunities.

Ulta Beauty

Small caps approach all-time highs, Eli Lilly at key level, 5 stocks in buy zones as Dow Jones futures surge. Ulta Beauty posts strong earnings. Robinhood leads new buys.

Merck & Co., Inc. has raised $8 billion through a multi-tranche notes offering, including various debt instruments with maturities ranging from 2029 to 2065. The offering closed on December 4, 2025, under the company's shelf registration statement filed with the SEC. This capital raising effort involves several series of notes with varying interest rates and maturities.

Reuters

Merck Raises $8 Billion in Multi-Tranche Notes Offering

AMGN

Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

Dow Jones

Amgen

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

Eli Lilly & Co. (LLY) shares fell 1.85% to $1,014.49 on Thursday, marking the sixth consecutive day of losses. The stock underperformed compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. It closed 8.77% below its 52-week high. Trading volume was slightly below the 50-day average. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

INTC

The S&P 500 index closed flat, with the healthcare sector down 0.9%, consumer staples down 0.8%, technology up 0.3%, energy up 0.3%, and telecommunications up 0.4%. The Nasdaq 100 index fell 0.2%, Intel dropped 7.7%, ON Semiconductor fell 4.3%, Micron Tech dropped 3.5%, ASML ADR fell 2.9%, Meta rose 2.5%, and Applovin increased by 3.6%. 3M fell 2.3%, UnitedHealth, Johnson & Johnson, and other Dow components dropped more than 1.4%, while NVIDIA rose 2% and Salesforce increased by 4.2%

Wallstreetcn

Intel

ON Semiconductor

Micron Tech

Scotiabank raised its target price for Merck & Co., Inc. (NYSE:MRK) from $105.00 to $120.00, giving the stock a "sector outperform" rating. This suggests a potential upside of 18.98% from the current price. Other analysts have mixed ratings, with some upgrading and others downgrading their ratings. Merck's recent earnings report showed a revenue increase of 3.7% year-over-year and an EPS of $2.58, beating estimates. The company has set its FY 2025 guidance at 8.930-8.980 EPS.

Scotiabank Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price